1.14
0.06 (5.56%)
| Penutupan Terdahulu | 1.08 |
| Buka | 1.08 |
| Jumlah Dagangan | 21,499 |
| Purata Dagangan (3B) | 101,008 |
| Modal Pasaran | 14,010,867 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.00 |
| Harga / Jualan (P/S) | 0.370 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Mar 2026 |
| Margin Keuntungan | -86.05% |
| Margin Operasi (TTM) | -130.50% |
| EPS Cair (TTM) | -14.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -40.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 32.10% |
| Nisbah Semasa (MRQ) | 2.09 |
| Aliran Tunai Operasi (OCF TTM) | -43.13 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.05 M |
| Pulangan Atas Aset (ROA TTM) | -52.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Allurion Technologies, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.63 |
|
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.67% |
| % Dimiliki oleh Institusi | 46.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 31 Dec 2025 | 5,891,430 |
| Lunt Capital Management, Inc. | 31 Dec 2025 | 166,666 |
| Anson Funds Management Lp | 31 Dec 2025 | 59,881 |
| Empery Asset Management, Lp | 31 Dec 2025 | 59,881 |
| Hudson Bay Capital Management Lp | 31 Dec 2025 | 59,880 |
| L1 Global Manager Pty Ltd | 31 Dec 2025 | 59,880 |
| Heights Capital Management, Inc | 31 Dec 2025 | 59,880 |
| Unisphere Establishment | 31 Dec 2025 | 49,695 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices |
| 12 Jan 2026 | Pengumuman | Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results |
| 25 Nov 2025 | Pengumuman | Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |